title: CLINICAL APPLICATION OF RECOMBINANT ERYTHROPOIETIN IN BETA-THALASSAEMIA INTERMEDIA.
abstract: Research objective is to study the efficacy of recombinant erythropoietin (epoetin alfa) as alternative method of treatment beta-thalassemia intermedia. Study involved 58 patients with beta-thalassemia intermedia (23 women and 35 men). In all observed patients was defined levels of hemoglobin (Hb), red blood cells (RBC), erythrocyte indexes (MCV, MCH, MCHC), hemoglobin fractions (HbA, HbA2, HbF), serum ferritin, serum erythropoietin before and after administrated rEPO. All patients received rEPO during 6 month at the dose - 10000 IU subcutaneously. The majority of patients - 39 (67%) had a good response to rEPO (increase in hemoglobin level more than 20 g/l); 16 patients (28%) had a mean response (increase in Hb 10 - 20 g/l); in 3 (5%) patients occurred poor response to rEPO therapy (increase in Hb <10 g/l). After rEPO treatment of beta-thalassemia intermedia patients there was a statistically significant change in the number of RBC, levels of HbF and sEPO. The evaluation of interdependence between the indices of the baseline sEPO and increased Hb values in patients after rEPO treatment revealed the presence of the reverse direct relationship (r=-0.67). Based on the results, it can be concluded that the use of rEPO in complex therapy of beta-thalassemia intermedia leads to increased levels of Hb and consequently reducing the need for blood transfusions, and accordingly expected to prevent severe complications of blood transfusion (alloimmunization, hypersplenism, iron overload, contamination transmissible infections) facilitating normal growth and development, and a better quality of life.
authors.affiliation: Institute of Hematology and Transfusiology, Baku, Azerbaijan.
authors.forename: Ch
authors.initials: Ch
authors.lastname: Asadov
authors.affiliation: Institute of Hematology and Transfusiology, Baku, Azerbaijan.
authors.forename: Z
authors.initials: Z
authors.lastname: Alimirzoyeva
authors.affiliation: Institute of Hematology and Transfusiology, Baku, Azerbaijan.
authors.forename: M
authors.initials: M
authors.lastname: Hasanova
authors.affiliation: Institute of Hematology and Transfusiology, Baku, Azerbaijan.
authors.forename: T
authors.initials: T
authors.lastname: Mammadova
authors.affiliation: Institute of Hematology and Transfusiology, Baku, Azerbaijan.
authors.forename: A
authors.initials: A
authors.lastname: Shirinova
mesh_terms: D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D002648:Child; D000068817:Epoetin Alfa / Q000627:therapeutic use*; D005260:Female; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D055815:Young Adult; D017086:beta-Thalassemia / Q000097:blood / Q000188:drug therapy*
chemical_list: D006397:Hematinics; D000068817:Epoetin Alfa